ライフサイエンスコーパス: isobutyl

1 ective than those with large groups (propyl, isobutyl).

2 s phenyl, 4-pyridyl, 2-pyridyl, indolyl, and isobutyl.

3 d the sensitivity of CFTR to activation by 3-isobutyl 1-methyl xanthine (IBMX), as expected if these

4 Forskolin or 3-isobutyl-1-methyl xanthine (IBMX), 2 inducers of adenyla

5 ) and used the phosphodiesterase inhibitor 3-isobutyl-1-methyl-xanthine (IBMX) as a pharmacological t

6 We studied the effect of 3-isobutyl-1-methyl-xanthine (IBMX) on THIK-1 currents.

7 sults were obtained with the PDE inhibitor 3-isobutyl-1-methyl-xanthine (IBMX) or with 8-pCPT-cGMP an

8 vinpocetine, SKF-94120, dipyridamole, and 3-isobutyl-1-methyl-xanthine but is inhibited (IC50 = 35 m

9 or with the PKA activators forskolin plus 3-isobutyl-1-methyl-xanthine or dibutyryl cyclic adenosine

10 well by either the nonselective inhibitor 3-isobutyl-1-methyl-xanthine or the new selective PDE5 inh

11 phosphate (cAMP) (forskolin (1-10 microM), 3-isobutyl-1-methylxanthine (0.1-1 mM), rolipram (10 micro

12 e similar IC(50) values for the inhibitors 3-isobutyl-1-methylxanthine (20 microM) and sildenafil (Vi

13 mbination of forskolin (20 micromol/L) and 3-isobutyl-1-methylxanthine (20 micromol/L), also inhibite

14 elective phosphodiesterase (PDE) inhibitor 3-isobutyl-1-methylxanthine (20 mumol/L).

15 ntiated by the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (5x10(-5) mol/L).

16 omercuribenzene sulphonate (21 microM) and 3-isobutyl-1-methylxanthine (970 microM, partial inhibitio

17 ls by the combination of dexamethasone and 3-isobutyl-1-methylxanthine (DM) is suppressed by 2,3,7,8

18 nd its crystal structure as a complex with 3-isobutyl-1-methylxanthine (IBMX) at 1.55 A resolution.

19 The nonselective inhibitor 3-isobutyl-1-methylxanthine (IBMX) binds to a similar subp

20 s crystal structures in the unliganded and 3-isobutyl-1-methylxanthine (IBMX) bound forms at 1.9 and

21 The phosphodiesterase (PDE) inhibitor 3-isobutyl-1-methylxanthine (IBMX) did not elevate cGMP on

22 continuously treated with forskolin and/or 3-isobutyl-1-methylxanthine (IBMX) in light-dark (LD) and

23 se suppression and the increased effect of 3-isobutyl-1-methylxanthine (IBMX) observed in GADA+ donor

24 3-Isobutyl-1-methylxanthine (IBMX) or 8-bromoadenosine 3',

25 dogenous cAMP levels with either forskolin/3-isobutyl-1-methylxanthine (IBMX) or the V2 receptor agon

26 posed to VIP, carbachol, forskolin, and/or 3-isobutyl-1-methylxanthine (IBMX) to determine whether th

27 GMP, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weake

28 In the presence of 3-isobutyl-1-methylxanthine (IBMX), 10 microM SNC was suff

29 3-Isobutyl-1-methylxanthine (IBMX), a non-specific phospho

30 Moreover, 3-isobutyl-1-methylxanthine (IBMX), an inhibitor of cAMP p

31 glucose and 10 mmol/l arginine, 0.1 mmol/l 3-isobutyl-1-methylxanthine (IBMX), and 5 micromol/l carba

32 of RINm5F cells to cAMP-increasing agents, 3-isobutyl-1-methylxanthine (IBMX), and forskolin complete

33 A nonselective PDE inhibitor, 3-isobutyl-1-methylxanthine (IBMX), and the PDE3 selective

34 or without the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), decreased the period (

35 exposed to the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX), the circulating curren

36 was increased by the use of forskolin and 3-isobutyl-1-methylxanthine (IBMX), we show that increase

37 In transient transfections, forskolin plus 3-isobutyl-1-methylxanthine (IBMX), which increases intrac

38 the variants, leading to stable, forskolin+3-isobutyl-1-methylxanthine (IBMX)-activated whole-cell cu

39 NAP), and the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine (IBMX).

40 ntained in the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX).

41 owing stimulation with forskolin (FSK) and 3-isobutyl-1-methylxanthine (IBMX).

42 nged treatment with an adipogenic inducer, 3-isobutyl-1-methylxanthine (IBMX).

43 s with 5'-GMP, vardenafil, sildenafil, and 3-isobutyl-1-methylxanthine (IBMX).

44 resence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX, 750 microM) reversibly

45 Incubating cells with PDGF and 3-isobutyl-1-methylxanthine (IBMX, a phosphodiesterase inh

46 competent in succinate-, ketoisocaproate-, 3-isobutyl-1-methylxanthine (IBMX-), KCl-, and tolbutamide

47 r, 10 micromol/L; >3-fold), potentiated by 3-isobutyl-1-methylxanthine (IBMX; phosphodiesterase type

48 gamma (PPARgamma) by dexamethasone (DEX), 3-isobutyl-1-methylxanthine (MIX), and insulin.

49 sphodiesterase (cAMP-PDE) inhibitors, e.g. 3-isobutyl-1-methylxanthine [(IBMX) or caffeine, 10 mg/kg]

50 ASL; (ii). activating CFTR with forskolin/3-isobutyl-1-methylxanthine alkalinized NL ASL but acidifi

51 roinjection of matched doses (300 nmol) of 3-isobutyl-1-methylxanthine and 7-deacetyl-7-O-(N-methylpi

52 These effects were potentiated by 3-isobutyl-1-methylxanthine and attenuated by the adenylyl

53 ncreases in intracellular cAMP prompted by 3-isobutyl-1-methylxanthine and forskolin partially mimick

54 However, 3-isobutyl-1-methylxanthine and forskolin treatment of a m

55 secretion (GSIS), and insulin secretion to 3-isobutyl-1-methylxanthine and KCl were all reduced witho

56 in in complex with non-selective inhibitor 3-isobutyl-1-methylxanthine and kinetic analysis on the mu

57 in (PDE5/6cd) complexed with sildenafil or 3-isobutyl-1-methylxanthine and the Pgamma-inhibitory pept

58 d be prevented by dibutyryl cyclic-cAMP or 3-isobutyl-1-methylxanthine and the somatostatin (SST) rec

59 Release was also stimulated by 3-isobutyl-1-methylxanthine and was additive with forskoli

60 DE6 with vardenafil or sildenafil (but not 3-isobutyl-1-methylxanthine and zaprinast) induced a disti

61 induced by 10 microm forskolin, 40 microm 3-isobutyl-1-methylxanthine caused a 50% reduction in myos

62 These structures together with the PDE5A1-isobutyl-1-methylxanthine complex show that the H-loop (

63 in complex with the nonselective inhibitor 3-isobutyl-1-methylxanthine have been determined at medium

64 skolin and the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine in proportion to increases in

65 resence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine in the medium, suggesting extr

66 3-isobutyl-1-methylxanthine increased insulin secretion bu

67 ment with the broad-spectrum PDE inhibitor 3-isobutyl-1-methylxanthine induced T cell CREB phosphoryl

68 The receptor inhibitor 3-isobutyl-1-methylxanthine inhibited the calcium response

69 reatment with forskolin, 8-bromo-cAMP, and 3-isobutyl-1-methylxanthine or by overexpression of the ca

70 3-Isobutyl-1-methylxanthine potentiated ATP-induced calciu

71 f T cells with 8-bromo cAMP, forskolin, or 3-isobutyl-1-methylxanthine prevented the CD47-mediated ap

72 ty, Km for cGMP, and IC50 for zaprinast or 3-isobutyl-1-methylxanthine were found among wild-type and

73 hibitors, it is most potently inhibited by 3-isobutyl-1-methylxanthine with an IC(50) of 2.1 microM.

74 :5'-cyclic monophospate sodium), and IBMX (3-isobutyl-1-methylxanthine) also changed the splicing pat

75 0 nM forskolin, 1 mM 8-bromo-cAMP, or 1 mM 3-isobutyl-1-methylxanthine) had no effect on the amplitud

76 clase activity was measured with the IBMX (3-isobutyl-1-methylxanthine) jump technique.

77 potent phosphodiesterase inhibitor, IBMX (3-isobutyl-1-methylxanthine).

78 nhibit the response of other ORNs to IBMX (3-isobutyl-1-methylxanthine)/forskolin in a PI3K-dependent

79 of 1) phorbol myristic acid, forskolin and 3-isobutyl-1-methylxanthine, 2) BPDZ 154, or 3) 4-phenylbu

80 t by dPGJ2 was enhanced in the presence of 3-isobutyl-1-methylxanthine, a cAMP phosphodiesterase inhi

81 In Leydig cells from wild-type mice, 3-isobutyl-1-methylxanthine, a compound that inhibits all

82 + and blocked by 2',5'-dideoxyadenosine or 3-isobutyl-1-methylxanthine, an inhibitor of phosphodieste

83 Forskolin, 3-isobutyl-1-methylxanthine, and 8-bromo-cAMP (8-Br-cAMP)

84 f Tudor-SN (MEF-KO) impairs dexamethasone, 3-isobutyl-1-methylxanthine, and insulin (DMI)-induced adi

85 that increase [cAMP] (forskolin, rolipram, 3-isobutyl-1-methylxanthine, and papaverine) or mimic cAMP

86 Rp-cAMPs and was mimicked by 8-bromo-cAMP, 3-isobutyl-1-methylxanthine, and Sp-cAMP.

87 cles with the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine, and the adenylate cyclase act

88 P, or with the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine, caused a rightward shift in t

89 nts known not to act on the cyclase, or by 3-isobutyl-1-methylxanthine, creatine phosphate, or creati

90 increase in tyrosinase activity by either 3-isobutyl-1-methylxanthine, dibutyryl cAMP, or forskolin.

91 acid methyl ester hydrochloride (T-0156), 3-isobutyl-1-methylxanthine, EDTA, or cGMP, but not by cAM

92 ibition of phosphodiesterase activity with 3-isobutyl-1-methylxanthine, indicating that alpha-adrener

93 Following treatment with these diols or 3-isobutyl-1-methylxanthine, melanin and tyrosinase activi

94 PDE5 constructs had similar affinities for 3-isobutyl-1-methylxanthine, sildenafil, tadalafil, and UK

95 187 or a combination of dibutyryl cAMP and 3-isobutyl-1-methylxanthine, which increase intracellular

96 3-isobutyl-1-methylxanthine, which potentiates the cGMP/cA

97 PDE inhibitors for their ability to mimic 3-isobutyl-1-methylxanthine-induced ATF-1/CREB phosphoryla

98 The forskolin/3-isobutyl-1-methylxanthine-stimulated whole-cell conducta

99 cts from monolayers treated with forskolin/3-isobutyl-1-methylxanthine.

100 lone before CFTR activation with forskolin/3-isobutyl-1-methylxanthine.

101 of CFTRDeltaF508 channel activity by 2 mm 3-isobutyl-1-methylxanthine.

102 PDE5 inhibitors, sildenafil, or zaprinast 3-isobutyl-1-methylxanthine.

103 resence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine.

104 8, including the nonspecific PDE inhibitor 3-isobutyl-1-methylxanthine.

105 cromol/l forskolin, 1 mmol/l 8-Br-cAMP, or 3-isobutyl-1-methylxanthine.

106 chlorophenylthio-cAMP, dibutyryl-cAMP, and 3-isobutyl-1-methylxanthine.

107 s of protein kinase A such as forskolin or 3-isobutyl-1-methylxanthine.

108 l preconstriction but not glibenclamide or 3-isobutyl-1-methylxanthine.

109 cipal cells after stimulation by forskolin/3-isobutyl-1-methylxanthine.

110 ulating pGC by ANP/BNP, or blocking PDE by 3-isobutyl-1-methylxanthine/zaprinast caused significant i

111 pendent protein kinase (PKA), MgATP, cGMP, 3-isobutyl-1-methylxanthine], shown earlier to produce Ser

112 1bR)-9-(3-fluoropropoxy)-2-(hydroxymethyl)-3-isobutyl-10-methoxy-2,3,4,6, 7,11b-hexahydro-1H-pyrido[2

113 an-13-yl)-9-methyl-but-11-enyl benzoate (1), isobutyl-13-(6-(benzoyloxy)-10-methylpentyl)-tetrahydro-

114 piperettine, pellitorine, guineensine, and N-isobutyl-2,4,14-eicosatrienamide were linked with severa

115 ison and decreased towards maturation, and 3-isobutyl-2-methoxyprazine decreased with increasing matu

116 s (TSS) and proline, and lower malic acid, 3-isobutyl-2-methoxypyrazine (IBMP) and arginine.

117 irteen rootstocks on the concentrations of 3-isobutyl-2-methoxypyrazine (IBMP), 3-isopropyl-2-methoxy

118 eloped with fused spectral data to predict 3-isobutyl-2-methoxypyrazine (IBMP), pH, total tannins (Ta

119 ethyl alcohol, but lower concentrations of 3-isobutyl-2-methoxypyrazine and ethyl esters, indicating

120 e identified as (Z)-1,5-octadien-3-one and 3-isobutyl-2-methoxypyrazine.

121 ibitor batimastat ([4-(N-hydroxyamino)-2-(R)-isobutyl-3-(S)-(2-thiophenethiomethyl)s uccinyl]-(S)-phe

122 rmined using two representative volatiles: 2-isobutyl-3-methoxypyrazine (IBMP) and linalool.

123 We observe that lithium (S)-N-isobutyl-3-methyl-1-((triisopropylsilyl)oxy)butan-2-amid

124 opylsilyl)oxy)ethyl)propan-2-amine, or (S)-N-isobutyl-3-methyl-1-((triisopropylsilyl)oxy)butan-2-amin

125 The ionic liquid, 1-isobutyl-3-methylimidazolium bis(trifluoromethane-sulfon

126 We have examined the effects of 1-isobutyl-3-methylxanthine (IBMX) and forskolin, agonists

127 Moreover, when administered to mice, 1-isobutyl-3-oxo-3,5,6,7-tetrahydro-2H-cyclopenta[c]pyridi

128 rom hydrogen substitution by isopropyl (3d), isobutyl (3f), cyclopentyl (3g), and pyrano- (2) inhibit

129 ective process for the preparation of 1 from isobutyl (3S)-3-[methyl[(1S)-1-phenylethyl]amino]butanoa

130 ists 3-N-propylxanthine (enprofylline) and 3-isobutyl-8-pyrrolidinoxanthine (IPDX) on AdoR-mediated H

131 ists 3-N-propylxanthine (enprofylline) and 3-isobutyl-8-pyrrolidinoxanthine (IPDX), and the A(1)-sele

132 ced it, and the selective A(2B) antagonist 3-isobutyl-8-pyrrolidinoxanthine prevented it.

133 AT2 inhibitor Ro 4-1284 (2-hydroxy-2-ethyl-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7-hexahydrobenzo[al ph

134 ne ([(18)F]FP-DTBZ), [(18)F](+)-2-oxiranyl-3-isobutyl-9-(3-fluoropropoxy)-10-methoxy-2,3,4,6,7,11b-he

135 demonstrate the utility of this approach for isobutyl acetate (IBA) production, wherein IBA productio

136 nversion of the alcohol function to acetate, isobutyl acetate (TIDBIBA), or to trimethyl acetate lead

137 ome of the compounds in the spreads, such as isobutyl acetate, butyl butyrate, 3-hexen-1-yl acetate o

138 lin for MPX and acetaldehyde diethyl acetal, isobutyl acetate, ethyl isovalerate and guaiacol for CRE

139 -borne odorants ((methyl ethyl ketone (MEK), isobutyl alcohol (i-BuAl), benzene (B), toluene (T), p-x

140 Capabilities are demonstrated using isobutyl alcohol droplets.

141 uM of the NHE1-specific inhibitor N-Methyl-N-isobutyl Amiloride (MIA) dramatically disrupted branchin

142 ibition of the Na+/H+ antiporter with methyl isobutyl amiloride (MIA) would decrease postischemic per

143 opropyl) amiloride or 10microM 5-(N-methyl-N-isobutyl) amiloride, both selective inhibitors of Na(+)-

144 since it could be inhibited by 5-(N-methyl-N-isobutyl)amiloride and by anti-NHX1 antibodies.

145 However, the larger 1,3-dialkyl groups (isobutyl and butyl) resulted in a decrease in both A(2B)

146 ee triangular macrocycles bearing isopropyl, isobutyl, and isopentyl side chains were synthesized and

147 meric peptoids decorated with N-isopropyl, N-isobutyl, and N-benzyl substituents.

148 active octanoic acid esters (ethyl-, butyl-, isobutyl- and (iso)amyl octanoate) using lipase Palatase

149 tammetry of the ethyl-, n-propyl-, n-butyl-, isobutyl-, and adenosyl-substituted cobalamin was studie

150 carbon and the new stereocenter bearing the isobutyl appendage corresponding to that of the alkaloid

151 Herein we report that isobutyl-beta-C-galactoside (IBCG) is also a promising i

152 The substituents employed were the isobutyl, butyl, and benzyl groups to give peptidomimeti

153 (PLG) was substituted at the 3-position with isobutyl, butyl, and benzyl moieties to give the PLG pep

154 samples (food, cosmetics and water) based on isobutyl chloroformate (IBCF) derivatisation and preconc

155 ides of carboxylic acids were prepared using isobutyl chloroformate and transformed to the correspond

156 ion (SBSE) with in situ derivatization using isobutyl chloroformate, followed by gas chromatographic

157 he nerve agent metabolites ethyl, isopropyl, isobutyl, cyclohexyl, and pinacolyl methylphosphonic aci

158 plant morphogenetic processes, from which N-isobutyl decanamide is one of the most active compounds

159 N-isobutyl decanamide treatment exacerbates the dhm1 pheno

160 s the isolation and characterization of an N-isobutyl decanamide-hypersensitive (dhm1) mutant of Arab

161 hyl, 2-ethyl, 2-n-propyl, 2-isopropyl, and 2-isobutyl derivatives of dihydrotetrabenazine.

162 acetic acid] and pregabalin (PGB) [(S)-(+)-3-isobutyl-GABA or (S)-3-(aminomethyl)-5-methylhexanoic ac

163 Gabapentin (GBP) and S(+)-3-isobutyl-gamma-aminobutyric acid (IBG) are anticonvulsan

164 Attempts to replace the isobutyl group at P1' with small cyclic moieties caused

165 er by replacing the cyclohexane ring with an isobutyl group attached either to position 4 or position

166 n the 3'-pyridyl ring and variation of the 3-isobutyl group gave potent compounds (pK(i) > 9.0) with

167 at with a phenyl group, and an anion with an isobutyl group has the weakest chiral recognition).

168 , the simulations suggest that directing the isobutyl group into the minor groove causes the groove t

169 herein the steric bulk associated with the N-isobutyl groups increases the energy barrier required to

170 For example, the Janus particle with isobutyl groups on one POSS and carboxylic groups on the

171 nt with this, we now report that addition of isobutyl groups to the PNA backbone hinders aggregation

172 was explored with methyl, ethyl, butyl, and isobutyl groups.

173 of the 3-substituent was benzyl > n-butyl > isobutyl > H.

174 From these studies, a new zirconocene isobutyl hydride complex, Cp' '(2)Zr(CH(2)CHMe(2))(H) (C

175 tive elimination for a family of zirconocene isobutyl hydride complexes, Cp(CpR(n)())Zr(CH(2)CHMe(2))

176 ze N-N bond formation converting O-(l-seryl)-isobutyl hydroxylamine into N-(isobutylamino)-l-serine.

177 e)G and N2-ethyl(Et)G, partially bypassed N2-isobutyl(Ib)G and N2-benzylG, and was blocked at N2-CH2(

178 y bypassed N2-methyl(Me)G, N2-ethyl(Et)G, N2-isobutyl(Ib)G, N2-benzyl(Bz)G, and N2-CH2(2-naphthyl)G b

179 (beta-naphthyl)cyclohexyl auxiliaries, using isobutyl iodide and benzyl bromide as model electrophile

180 Conventional 201TI and hexakis 2-methoxy-2-isobutyl isonitrile studies are less accurate as compare

181 s in the study are ethyl, n-propyl, n-butyl, isobutyl, isopropyl, sec-butyl, and tert-butyl.

182 ase now accepts the analogous ketone, methyl isobutyl ketone (MIBK), which corresponds to exchange of

183 into high volume industrial ketones: methyl isobutyl ketone (MIBK, yield 84%), diisobutyl ketone (DI

184 yed focus on the determination of (1) methyl isobutyl ketone in water over the range of 1-160 ppm, (2

185 e, using azeotropic distillation with methyl isobutyl ketone to drive the dehydration.

186 oroethylene, methyl tert-butyl ether, methyl isobutyl ketone), diffusion-limited (theoretical), R d,

187 y analyzing the standard solutions of methyl isobutyl ketone, heptanone, nonanone, and acetophenone a

188 Samples were diluted in methyl isobutyl ketone.

189 ability is shown for both acetone and methyl isobutyl ketone.

190 ns that directly convert primary alcohols to isobutyl ketones.

191 ed with 10 microM forskolin and 300 microM 3-isobutyl-L-methylxanthine and voltage-clamped with pipet

192 elimination to a [(C5Me5)2Ln][(mu-Ph)2BPh2]/isobutyl lithium route.

193 st 4.2 LD(50) of S-(2-(diethylamino)ethyl) O-isobutyl methanephosphonothioate without perturbation of

194 (IPMP), secbutyl methoxypyrazine (SBMP) and isobutyl methoxypyrazine (IBMP) in wine.

195 ignificantly influenced by harvest date were isobutyl methoxypyrazine, C(6) alcohols and hexyl acetat

196 sters tested, the hydrolysis product of rVX, isobutyl methyl phosphonate, was the best substrate with

197 The effects of isobutyl methyl xanthine (IBMX), an inhibitor of phospho

198 Addition of forskolin and isobutyl-methyl-xanthine during hypoxia resulted in reve

199 ophenylthio) (8-CPT)-cAMP (100 micromol/L) + isobutyl methylxanthine (100 micromol/L).

200 he nonselective phosphodiesterase inhibitor, isobutyl methylxanthine (IBMX) increased the potency of

201 completely by the nonselective PDE inhibitor isobutyl methylxanthine and also by the selective PDE 3B

202 rapid and sustained response to glucose plus isobutyl-methylxanthine in perifusion studies that is cl

203 depots, under identical culture conditions (isobutyl-methylxanthine, dexamethasone, and insulin), re

204 eincubation with an MMP-3 inhibitor, NNGH [N-isobutyl-N-(4-methoxyphenylsulfonyl)-glycylhydroxamic ac

205 eutralizing antibody and the MMP inhibitor N-isobutyl-N-(4-methoxyphenylsulfonyl)glycyl hydroxamic ac

206 d a MMP inhibitor, (2S:-allyl-N:-hydroxy-3R:-isobutyl-N:-(1S:-methylcarbamoyl-2-ph enylet hyl)-succin

207 but did not show protonated molecules for an isobutyl or benzylic EHNA derivative, suggesting the lat

208 A hydrophobic group such as isobutyl or isopropoxyl was found to be optimal at the 4

209 n which the electrophilic oxygen is formally isobutyl or neopentyl.

210 erally more potent than hydrogen, isopropyl, isobutyl, or benzyl.

211 e addition of alkyl halides such as methyl-, isobutyl-, or neopentyl halides was also rapid at room t

212 omparison of rate constant for hydrolysis of isobutyl phenyl carbonate with benzyl phenyl carbonate s

213 amines R' 'NH(2) (R' ' = n-propyl, n-butyl, isobutyl, phenyl, 4-methylphenyl, 4-(dimethylamino)pheny

214 th simulations) for the OIPC diethyl(methyl)(isobutyl)phosphonium hexafluorophosphate ([P(1,2,2,4)][P

215 We found that di-isobutyl phthalate (DiBP) and di- n-butyl phthalate (DnB

216 late (DEHP), di-n-butyl phthalate (DnBP), di-isobutyl phthalate (DiBP), and butyl-benzyl phthalate (B

217 hyl-5-carboxypentyl) phthalate (MECPP), mono-isobutyl phthalate (MiBP), mono-n-butyl phthalate (MBP),

218 evels of mono-n-butyl phthalate (MnBP), mono-isobutyl phthalate (MiBP), monobenzyl phthalate (MBzP),

219 ns of mono-n-butyl phthalate (MnBP) and mono-isobutyl phthalate (MiBP).

220 ratio [OR], 1.12 [95% CI, 0.98-1.27]), mono-isobutyl phthalate (OR, 1.16 [95% CI, 1.00-1.34]), mono(

221 thalate [DEHP]) decreased, while those of di-isobutyl phthalate [DiBP], di-isononyl phthalate [DiNP],

222 (mCPP), mono-n-butyl phthalate (mBP), mono(2-isobutyl) phthalate (miBP), monobenzyl phthalate (mBzP),

223 m for para-dichlorobenzene, 6,800 ppm for di(isobutyl) phthalate, 7,700 ppm for diethyl phthalate, an

224 methylphosphonic acid (R = ethyl, isopropyl, isobutyl, pinacolyl (3,3-dimethyl-2-butyl), cyclohexyl,

225 nded set of 16 isobaric reagents based on an isobutyl-proline immonium ion reporter structure (TMTpro

226 le neopentyl protecting group and the labile isobutyl protecting group were utilized in the synthesis

227 methoxy-3-isopropyl pyrazine and 2-methoxy-3-isobutyl pyrazine in asparagus odour.

228 inoethyl methylphosphonothioate) and R-VX (O-isobutyl-S-2-diethylaminoethyl methylphosphonothioate),

229 hobic moiety to the lactam ring to mimic the isobutyl side chain of the leucyl residue of PLG would i

230 ation of the malonylidene unit to include an isobutyl substituent at C3 affords a photosubstrate whic

231 Combination of the optimal 4'-isobutyl substituent with the 2'-amino function afforded

232 , ethyl, propyl, and to a much lesser extent isobutyl substituents at C(2) (R configuration only).

233 In this case, a 2'-isobutyl-substituted spiro[indoline-3,3'-pyrrolenine] re

234 rk on enantioselective desymmetrization of N-isobutyl tertiary alkylamines.

235 f these fruit revealed the accumulation of 2-isobutyl-tetrahydrothiazolidine-4-carboxylic acid, a kno

236 roved to be an alternating copolymer made of isobutyl vinyl ether and the renewable raw material furf

237 up as well as a short alkyl chain (propyl or isobutyl) which defined the 0/1 molecular binary code.

238 sphodiesterase (PDE) inhibitors, 1-methyl-3- isobutyl xanthine and theophylline and rolipram, a speci